HDAC2 and diffuse large B-cell lymphoma: HDAC2 is consistently overexpressed in both DLBCL1 and DLBCL2 cohorts and higher expression of HDAC2 is significantly associated with inferior clinical outcome in DLBCL patients (P = 0.0125 and HR = 1.915 in DLBCL1 cohort; P = 0.0002 and HR = 2.318 in DLBCL2 cohort), regardless of treatment regimens.